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Abstract 
BACKGROUND: The purpose of the present study was the analysis of the trends in case fatality 
rate of acute myocardial infarction (AMI) in Isfahan, Iran. This analysis was performed based on 
gender, age groups, and type of AMI according to the International Classification of Diseases, 
version 10, during 2000-2009. 
METHODS: Disregarding the Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease (MONICA), this cohort study considered all AMI events registered 
between 2000 and 2009 in 13 hospitals in Isfahan. All patients were followed for 28 days. In 
order to assess the case fatality rate, the Kaplan-Meier analysis, and to compare survival rate, 
log-rank test were used. Using the Cox regression model, 28 days case fatality hazard ratio (HR) 
was calculated. 
RESULTS: In total, 12,900 patients with first AMI were entered into the study. Among them, 
9307 (72.10%) were men and 3593 (27.90%) women. The mean age in all patients increased 
from 61.36 ± 12.19 in 2000-2001 to 62.15 ± 12.74 in 2008-2009, (P = 0.0070); in women, from 
65.38 ± 10.95 to 67.15 ± 11.72 (P = 0.0200), and in men, from 59.75 ± 12.29 to 59.84 ± 12.54  
(P = 0.0170),. In addition, the 28 days case fatality rate in 2000-2009 had a steady descending 
trend. Thus, it decreased from 11.20% in 2000-2001 to 07.90% in 2008-2009; in men, from 
09.20% to 06.70%, and in women, from 16.10% to 10.90%. During the study, HR of case fatality 
rate in 2000-2001 declined; therefore, in 2002-2003, it was 0.93 [95% confidence interval  
(CI) = 0.77-1.11], in 2004-2005, 0.88 (95% CI = 0.73-1.04), in 2006-2007, 0.67 (95% CI = 0.56-
0.82), and in 2008-2009, 0.69 (95% CI = 0.56-0.82). 
CONCLUSION: In Isfahan, a reduction was observable in the trend of case fatality rate in both 
genders and all age groups. Thus, there was a 29.46% reduction in case fatality rate (27.17% in 
men, 32.29% in women) during the study period. 
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Introduction 
Coronary heart disease (CHD) remains one of the 
leading causes of death in both genders in developed 
countries.1 The incidence of mortality due to 
cardiovascular disease has been diminishing over the 
previous 3 decades in many developed countries.2 
Reduced incidences, promotion of secondary 
prevention measures, use of new treatments during 
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the acute phase, and improved survival after 
myocardial infarction (MI) have contributed to the 
declining mortality rates.3-5 However, MI is a primary 
cause of mortality and disability in the Iranian 
population.6 Age, sex, cardiovascular risk factors, 
coronary history, acute MI (AMI) location, 
complications, treatments received during 
hospitalization and after hospital discharge, and the 
type of hospital are among the variables that may 
influence early or late mortality following an AMI.7-10 
Most of the centers showed a decline in short-term 
case fatality rate, but the Isfahan center, Iran, did not.5 
The purpose of the present study was the analysis of 
the trends of case fatality rate of AMI in Isfahan and 
Najafabad based on gender, age groups, and type of 
AMI in patients treated during 2000-2009. Type of 
AMI was determined according to the International 
Classification of Disease, version 10 (ICD10) and 
using streptokinase. 
Materials and Methods 
Isfahan is a city in the center of Iran, an Eastern 
Mediterranean country, and is the second largest 
city of Iran. Previous studies have shown a relatively 
high rate of cardiovascular risk factors in this 
industrial city.11-15 
During the study period, about 13 hospitals were 
admitting and managing patients with CHD in 
Isfahan. More than 75% of patients who had 
experienced MI were managed in 4 public hospitals 
and the rest in the remaining 9 private hospitals. 
Except for military hospitals, which did not allow 
access to their patients’ records, other hospital 
records were evaluated. Among these hospitals, 4 
were private and 9 public or university hospitals.16 
In this registry, all possible CHD events were 
registered disregarding the Multinational Monitoring 
of Trends and Determinants in Cardiovascular 
Disease (MONICA) age limitation. In this study, the 
MONICA definition (non-fatal definite events and 
fatal definite or possible events) is used for MI events. 
Moreover, only first events and patients classified as 
one group according ICD10 are included. 
The research team involved in the program 
consisted of cardiologists and general practitioners, a 
number of nurses trained in receiving and recording 
patients’ information, and professional biostatistician 
and epidemiologist. Identification and separation of 
patients with AMI based on ICD10 was performed by 
a cardiologist. Hospital discharge lists were used for 
case finding. Records of patients hospitalized in 
cardiology wards, coronary care units, or other wards 
but under the complete or partial supervision of 
cardiologists, were evaluated for possible signs and 
symptoms of CHD events. Basic information related 
to patients were collected by trained nurses, who used 
special forms to interview patients or obtained 
information from their hospital records. Symptoms 
and cardiac enzymes codes were classified in a manner 
similar to the MONICA project.17 They summarized 
accurate records in special checklists containing in-
formation on age, sex, event and hospitalization dates, 
symptoms, history of previous MI, enzymes, 
admission electrocardiogram, whether the event was 
iatrogenic, survival status at discharge and after 28 
days follow-up, and whether thrombolytic therapy was 
used during hospitalization. An expert nurse with 
special training in the MONICA registration system 
checked the filled records. Moreover, 10% of the 
checklists were randomly chosen and refilled by the 
expert nurse using the original hospital records and 
compared with those completed by registered nurses 
to see if any mistakes occurred. Then, data was 
collected from the Isfahan Cardiovascular Research 
Center (ICRC). As the center of Isfahan Province, MI 
patients who live in other cities of the province are 
also admitted to these hospitals. In order to calculate 
MI survival rate in Isfahan, only records from Isfahan 
and Najafabad city inhabitants were included in the 
study.16 
A period of 28 days was used to define the case-
fatality rate and to distinguish between events.18 All 
discharged MI patients were followed using 
telephone calls, and if not available, reached 
through their address. The patients or close family 
members were asked about patients’ health status. If 
a patient had died during the first 28 days after the 
event, death scenario was asked.16 Detailed 
descriptions of the methods used in this project 
have been provided in previous reports.16,19-24 
Overall, 14,450 patients (10,334 men and 4116 
women) with first AMI, who were inhabitants of 
Isfahan and Najafabad were entered into the study. 
Subsequently, 886 patients (564 men and 322 
women) were excluded because their AMI type was 
not determined according to the ICD10. 
Furthermore, 118 patients (82 men and 36 women) 
were exclude from the study, because they died 
during the 28 days after the first attack without any 
sign of cardiovascular disease and due to accident, 
suicide, homicide, chronic obstructive pulmonary 
disease, cancer, liver cirrhosis, rheumatic heart 
disease, vascular disease, or atherosclerosis. In 
addition, 418 patients (292 men and 126 women) 
were excluded because outcome was unknown. 
Moreover, 128 patients (89 men and 39 women) 
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were excluded from the study, because the exact date 
of occurrence or death from the disease was not 
specified and the 28 days duration after the attack 
could not be calculated in these cases.17 Therefore, 
12,900 patients, 9307 (72.15%) men and 3593 
(27.85%) women, remained in the study. 
The study period, from 2000 to 2009, was 
divided into 5 2-year periods (2000-2001, 2002-
2003, 2004-2005, 2006-2007, and 2008-2009). Case 
fatality rates were adjusted for age through direct 
standardization. Standardization was based on 4 age 
groups; ≤ 40, 41-60, 61-80, and ≥ 81 years. In order 
to compare age average in the study, t-test and 
analysis of variance (ANOVA) were used. To assess 
the case fatality rate according to each period, 
Kaplan-Meier analysis, and to compare case fatality 
rate, log-rank test were used. Short-term (28 days) 
case fatality hazard ratio (HR) was calculated using 
the Cox regression model for every 2-year period. 
The first period (2000-2001) was considered as 
reference, and other periods were compared with 
this group and 95% confidence interval (CI) was 
calculated. The trend of streptokinase use in the 
treatment of AMI in hospitals was evaluated in every 
2-year period. SPSS software (version 15, SPSS Inc., 
Chicago, IL, USA) was used for data analysis. The 
significance value was set to P < 0.050. 
Results 
In total, this study included 12,900 fatal and non-
fatal first AMI events, of which 9307 (72.15%) were 
men and 3593 (27.85%) women. Sex ratio 
(male/female) was 2.59. Patient’s demographic and 
clinical data is presented in table 1. The distribution 
of first AMI and 28 days case fatality rate in 10 
years (for every 2 years separately) of the study 
periods is shown in table 2. Of the 12,900 patients 
with AMI entered into the study, 1198 died during 
the 28 days after their MI event (overall case fatality 
rate = 09.30% and survival rate = 90.70%). Of the 
9307 men, 697 died (case fatality rate = 07.50% and 
survival rate = 92.50%) and of the 3593 women, 
501 died (case fatality rate = 13.90% and survival 
rate = 86.10%) (P < 0.001). 
A steady descending trend was observed in the 28 
days case fatality rate during the study period (2000-
2009); it decreases from 11.82% in 2000-2001 to 
07.90% in 2008-2009. In fact, we observed a 03.92% 
decrease in case fatality rate from 2000-2001 to 2008-
2009, and 29.46% improvement in survival rate 
compared to 2000-2001. However, this trend has 
been in both genders. Therefore, in men, it decreased 
from 09.20% in 2000-2001 to 06.70% in 2008-2009 
(meaning a 02.5% decrease in case fatality rate from 
2000-2001 to 2008-2009 and 27.17% improvement 
in survival rate compared to 2000-2001). In women, 
it decreased from 16.10% in 2000-2001 to 10.90% in 
2008-2009 (meaning a 05.20% decrease in case 
fatality rate from 2000-2001 to 2008-2009 and 
36.80% improvement in survival rate compared to 
2000-2001) (Table 2 and Figure 1). 
However, this trend was observed in HR of 28 
days case fatality rate from AMI during the study 
period. Thus, in comparison with 2000-2001, in  
2002-2003, 2004-2005, 2006-2007, and 2008-2009, HR 
was 0.93 (CI 95% = 0.77-1.11), 0.88 (CI 95% = 0.73-
1.04), 0.67 (CI 95% = 0.56-0.82), and 0.69  
(CI 95% = 0.56-0.82), respectively. This trend was 
observable in both genders. In men, HR, respectively, 
was 0.98 (CI 95% = 0.74-1.30), 0.95 (CI 95% = 0.75-
1.29), 0.73 (CI 95% = 0.54-0.98), and 0.67  
(CI 95% = 0.49-0.91). In women, it was 0.91  
(CI 95% = 0.72-1.15), 0.8 (CI 95% = 0.64-1.00), 0.66 
(CI 95% = 0.51-0.84), and 0.71 (CI 95% = 0.56-0.92), 
respectively (Table 2). 
Mean age of all patients was 61.80 ± 12.60; in men 
it was 60.00 ± 12.50 and in women  
66.72 ± 11.34. This difference was statically significant 
(P ≤ 0.0010). To examine changes in age of disease 
occurrence over time, the study period was divided 
into 5 2-year periods. Mean age of all patients 
increased from 61.36 ± 12.19 in the primary period 
(2000-2001) to 62.61 ± 12.81 in the final period  
(2008-2009). This difference was statically significant 
(P = 0.0070). There was a raising trend in mean age in 
men and women in the study period. For women, in 
the primary period, it was 65.38 ± 10.95 and in the 
final period was 67.15 ± 11.72 (P = 0.0200). For men, 
in the primary period, it was 59.75 ± 12.29 and in the 
final period 59.84 ± 12.54 (P = 0.0170) (Table 3). In 
addition, this trend was observed in mean age at time 
of death. Thus, in the primary period, it was  
68.00 ± 10.60 and in the final period, 71.40 ± 9.53  
(P = 0.0200). This trend was observed in men and 
women, but it was only significant in women. For 
women, in the primary period, it was 68.86 ± 10.41 
and in the final period, 73.11 ± 08.94 (P = 0.0440). 
For men, in the primary period, it was 67.40 ± 10.73, 
and in the final period, 70.31 ± 08.70 (P = 0.1640) 
(Table 3). 
Table 4 shows the trends of case fatality rate for 
each age group. Case fatality rate decreased in a 
steady pattern in all age groups with the increase in 
age. Consequently, there was a 60, 60, 19.31, and 
46.75 percent reduction in case fatality rate in the 
final period (2008-2009), compared to the primary 
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period (2000-2001), respectively, for < 40, 41-60, 
61-80, and > 81 age groups (Table 4). 
In this study, based on ICD10, AMI was classified 
into 6 groups; acute transmural MI of anterior wall, 
acute transmural MI of inferior wall, acute transmural 
MI of other site, acute transmural MI of unspecified 
site, acute sub endocardial MI and AMI, and 
unspecified. Because the number of patients in acute 
transmural MI of other sites and acute transmural MI 
of unspecified site was small and very unstable, we 
considered these two groups as one group. In Isfahan 
and Najafabad, based ICD10, from 2000 to 2009 no 
evident trend was observed in 10 years case fatality 
rate. However, difference in average case fatality rate 
between types of AMI, according to ICD10, was 
statistically significant (P < 0.0001) (Table 5). 
In addition, use of streptokinase in the treatment 
service during the study period had no clear trend. In 
average, 51.8% (minimum of 48.3% and maximum 
of 56.40%) of patients received streptokinase, 
55.70% in men (minimum of 52.20% and maximum 
of 61.80%) and 41.70% in women (minimum of 
38.20% and maximum of 44.70%). Furthermore, 
48.20% (minimum of 43.60% and maximum of 
51.70%) of patients did not receive streptokinase; 
47.80% in men (minimum of 38.20% and maximum 
of 47.80%) and 61.80% in women (minimum of 
55.30% and maximum of 61.80%) (Table 6). 
 
Table 1. Demographic and clinical data of hospitalized myocardial infarction (MI) patients in Isfahan 
Variables Men Women Total Live Death Total Live Death Total Live Death Total 
Age in men 
         
39 year and lower 427 98 525 336 114 450 763 212 975 
40-49 394 5 399 42 2 44 436 7 443 
50-59 1587 42 1629 225 11 236 1812 53 1865 
60-69 2423 102 2525 579 48 627 3002 150 3152 
70-79 2150 193 2343 933 123 1056 3083 316 3399 
80 year and older 1629 257 1886 977 203 1180 2606 460 3066 
Streptokinase          
Receiving 4864 317 5181 1269 229 1498 6133 546 6679 
Not receiving 3746 380 4126 1823 272 2095 5569 652 6221 
ICD, version 10          
Acute sub endocardial MI 2979 213 3192 950 126 1076 3929 339 4268 
Acute transmural MI of other sites 2650 109 2759 825 86 911 3475 195 3670 
Acute transmural MI of inferior wall 225 7 232 84 11 95 309 18 327 
Acute transmural MI of anterior wall 82 24 106 28 25 53 110 49 159 
AMI, unspecified 736 16 752 446 20 466 1182 36 1218 
Acute transmural MI of unspecified site 1938 328 2266 759 233 992 2697 561 3258 
The first center was referred          
Non-specialized hospitals 573 65 638 185 53 238 758 118 876 
Specialized hospital 7547 590 8137 2747 418 3165 10294 1008 11302 
Unknown 208 27 235 66 14 80 274 41 315 
Health networker clinic 282 15 297 94 16 110 376 31 407 
Symptoms          
Typical 7250 523 7773 2518 380 2898 9768 903 10671 
A typical 993 92 1085 376 48 424 1369 140 1509 
Others 339 75 414 183 69 252 522 144 666 
Miss 28 7 35 15 4 19 43 11 54 
Cardiac enzymes           
A typical 1026 61 1087 509 66 575 1535 127 1662 
Typical 6597 483 7080 2196 306 2502 8793 789 9582 
Others 780 45 825 291 43 334 1071 88 1159 
Not clear 207 108 315 96 86 182 303 194 497 
Hospital          
Academic hospitals 7894 650 8544 2842 465 3307 10736 1115 11851 
Privative hospitals 716 47 763 250 36 286 966 83 1049 
ICD: International Classification of Diseases; Cardiac enzymes: Lactate dehydrogenase, creatine kinase, and Troponin 
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Table 2. Trend of case fatality rate of acute myocardial infarction (AMI) according to gender in Isfahan and Najafabad 
from 2000 to 2009 
Years Total (n) Number of events Case fatality rate HR of case fatality (95% CI) 
Men     
Overall 9307 697 7.5 - 
2000-2001 1331 123 9.2 R 
2002-2003 1877 159 8.5 0.98 (0.74-1.30) 
2004-2005 2208 166 7.5 0.98 (0.75-1.29) 
2006-2007 2029 125 6.2 0.73 (0.54-0.98) 
2008-2009 1862 124 6.7 0.67 (0.49-0.91) 
Women     
Overall 3593 501 13.9 - 
2000-2001 533 86 16.1 R 
2002-2003 719 112 15.6 0.91 (0.72-1.15) 
2004-2005 893 139 15.6 0.81 (0.64-1.00) 
2006-2007 725 85 11.7 0.66 (0.51-0.84) 
2008-2009 723 79 10.9 0.71 (0.56-0.92) 
Total     
Overall 12900 1198 09.3 - 
2000-2001 1864 209 11.2 R 
2002-2003 2596 271 10.4 0.93 (0.77-1.11) 
2004-2005 3101 305 09.8 0.88 (0.73-1.04) 
2006-2007 2754 210 07.6 0.67 (0.56-0.82) 
2008-2009 2585 203 07.9 0.69 (0.57-0.84) 
R: Reference group; HR: Hazard ratio; CI: Confidence interval 
 
 
Figure 1. Trend of survival rate of acute myocardial infarction according to gender 
in Isfahan and Najafabad from 2000 to 2009 
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Table 3. Trend of change in mean age of patients with acute myocardial infarction (AMI) at time of occurrence and death in Isfahan and Najafabad from 2000 to 2009 
Years Number of 
men 
Mean age in men P Number of 
women 
Mean age in 
women 
P Number of patients 
Mean age in 
patients P 
Sex ratio 
(men/women) 
Age of disease occurrence           
Overall 9307 60.00 ± 12.54 
0.017 
3593 66.77 ± 11.37 
0.020 
12900 61.90 ± 12.60 
0.007 
2.59 
2000-2001 1331 59.75 ± 12.29 533 65.38 ± 10.95 1864 61.36 ± 12.19 2.49 
2002-2003 1877 59.77 ± 12.44 719 66.89 ± 11.14 2596 61.74 ± 12.51 2.61 
2004-2005 2208 59.60 ± 12.59 893 66.62 ± 11.45 3101 61.62 ± 12.68 2.47 
2006-2007 2029 60.13 ± 12.50 725 67.46 ± 11.34 2754 62.06 ± 12.63 2.79 
2008-2009 1862 59.84 ± 12.54 723 67.15 ± 11.72 2585 62.61 ± 12.81 2.57 
Age in death time           
Overall 697 68.12 ± 11.15 
0.164 
501 71.46 ± 10.27 
0.044 
1198 69.52 ± 10.91 
0.020 
1.40 
2000-2001 123 67.40 ± 10.73 86 68.86 ± 10.41 209 68.00 ± 10.60 1.43 
2002-2003 159 67.16 ± 11.30 112 71.27 ± 10.58 271 68.86 ± 11.17 1.41 
2004-2005 166 67.94 ± 11.20 139 71.40 ± 10.52 305 69.51 ± 11.00 1.19 
2006-2007 125 68.13 ± 12.40 85 72.90 ± 10.12 210 70.06 ± 11.74 1.47 
2008-2009 124 70.31 ± 8.70 79 73.11 ± 08.94 203 71.40 ± 09.53 1.56 
 
Table 4. Trend of case fatality rate of acute myocardial infarction (AMI) according to age groups in Isfahan and Najafabad from 2000 to 2009 
Age group < 40 41-60 61-80 > 81 
(year) Patients Death Case fatality rate (%) Patients Death Case fatality rate (%) Patients Death Case fatality rate (%) Patients Death Case fatality rate (%) 
Overall 556 11 1.97 5323 225 4.2 6285 804 12.8 736 159 21.6 
2000-2001 87 2 2.30 734 47 6.4 985 143 14.5 58 17 29.3 
2002-2003 119 4 3.40 1048 56 5.3 1309 175 13.4 120 36 30.0 
2004-2005 146 1 0.70 1333 59 4.4 1456 205 14.1 166 40 24.1 
2006-2007 96 3 3.10 1163 36 3.1 1315 138 10.5 180 33 18.3 
2008-2009 108 1 0.90 1045 26 2.5 1220 143 11.7 212 33 15.6 
 
Table 5. Trend of case fatality rate of acute myocardial infarction (AMI) according to type of AMI based on the International Classification of Diseases 10 (ICD10) in Isfahan and Najafabad from 2000 to 2009 
AMI 
based 
ICD10 
Acute transmural MI of 
anterior wall 
Acute transmural MI of 
inferior wall 
Acute transmural MI of other 
sites and acute transmural MI 
of unspecified site 
Acute subendocardial 
MI unspecified AMI  Total 
Total N 
(Death N) 
Case fatality 
rate (%) 
Total N 
(Death N) 
Case fatality 
rate (%) 
Total N 
(Death N) 
Case fatality rate 
(%) 
Total N 
(Death N) 
Case fatality 
rate (%) 
Total N 
(Death N) 
Case fatality 
rate (%) 
Total N 
(Death N) 
Case fatality 
rate (%) 
Overall 4268 (339) 9.1 3670 (195) 5.3 486 (67) 13.8 1218 (36) 3.0 3258 (561) 17.2 12900 (1198) 09.3 
2000-2001 74 (69) 9.5 602 (40) 6.6 192 (46) 24.0 200 (10) 5.0 145 (44) 30.3 1864 (209) 11.2 
2002-2003 94 (98) 9.9 836 (60) 7.2 90 (8) 08.9 260 (6) 2.3 416 (99) 23.8 2596 (271) 10.4 
2004-2005 996 (75) 5.0 888 (44) 5.0 102 (6) 05.9 269 (2) 0.7 846 (178) 21.0 3101 (305) 09.8 
2006-2007 762 (40) 5.2 707 (30) 4.2 74 (5) 06.8 265 (7) 2.6 946 (128) 13.5 2754 (210) 07.6 
2008-2009 791 (57) 7.2 637 (21) 3.3 28 (2) 07.1 24 (11) 4.9 905 (112) 12.4 2585 (203) 07.9 
AMI: Acute myocardial infarction; MI: Myocardial infarction; ICD10: International Classification of Diseases 10  
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Table 6. Trend of use of streptokinase in treatment of acute myocardial infarction (AMI) according to gender in Isfahan and Najafabad from 2000 to 2009 
Streptokinase 
Men Women Total 
Receiving 
streptokinase  
[n (%)] 
Not receiving 
streptokinase  
[n (%)] 
Streptokinase 
total [n (%)] 
Receiving 
streptokinase  
[n (%)] 
Not receiving 
streptokinase  
[n (%)] 
Streptokinase 
total [n (%)] 
Receiving 
streptokinase  
[n (%)] 
Not receiving 
streptokinase  
[n (%)] 
Streptokinase 
total [n (%)] 
Overall 5181 (55.7) 4126 (47.8) 9307 (100) 1498 (41.7) 2095 (58.3) 3593 (100) 6679 (51.8) 6221 (48.2) 12900 (100) 
2000-2001 823 (61.8) 508 (38.2) 1331 (100) 229 (43.0) 304 (57.0) 533 (100) 1052 (56.4) 812 (43.6) 1864 (100) 
2002-2003 1022 (54.4) 855 (45.6) 1877 (100) 291 (40.5) 428 (59.5) 719 (100) 1313 (50.6) 1283 (49.4) 2596 (100) 
2004-2005 1267 (57.4) 941 (42.6) 2208 (100) 399 (44.7) 494 (55.3) 893 (100) 1666 (53.7) 1435 (47.3) 3101 (100) 
2006-2007 1097 (54.1) 932 (45.9) 2029 (100) 303 (41.8) 422 (58.2) 725 (100) 1400 (50.8) 1354 (49.2) 2754 (100) 
2008-2009 972 (52.2) 890 (47.8) 1862 (100) 276 (38.2) 447 (61.8) 723 (100) 1248 (48.3) 1337 (51.7) 2585 (100) 
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Discussion 
In the present study, we have demonstrated a 
consistent decrease in case fatality rate following a first 
MI in Isfahan, during a 10 years period from 2000 to 
2009. The decreasing trend of case fatality rate was 
observable in both genders and all age groups. There 
was a 29.46% reduction in case fatality rate in the final 
period (2008-2009) compared with the primary period 
(2000-2001). A 27.17% decrease was observed in men, 
and 32.29% in women. Moreover, a 60% decrease in 
the ≤ 40 age group, 60% in 41-60 age group, 19.31% 
in 61-80, and 46.75% in ≥ 80 was observed. In 
addition, in the duration of the study, there was a 
decreasing trend in the HR of 28 days case fatality rate 
in all patients. 
In this study, the majority of patients were men 
(72.10% men and 27.90% women) and women 
were older (66.77 ± 11.37 vs. 60.00 ± 12.54 years; P 
< 0.0010). The 28 days case fatality rate was higher 
in women than men (13.90 vs. 07.50%;  
< 0.0001). In a study conducted by Carine Milcent 
et al. in the French Hospitals Database, most 
patients were men (70% men and 30% women) and 
women were older (75 vs. 63 years of age;  
P < 0.0010) and had a higher rate of hospital 
mortality (14.80 vs. 06.10%; P < 0.0001) than 
men.25 This was in agreement with the findings of 
the current study. However, the present analysis 
confirms the higher 28 days case fatality rate from 
AMI in women; the so-called “gender gap” reported 
in other studies.26-29 In previous studies, we 
observed that crude hospital mortality rates for 
AMI in women was higher than men. This 
difference may be partly due to the higher average 
age of women at the time of disease occurrence and 
higher prevalence of comorbidities in women 
compared with men.26 More frequent use of 
revascularization procedures in men may also 
account for the fewer deaths. Indeed, men with 
AMI tend to undergo more aggressive hospital 
treatments than women.30,31 We observed a similar 
result in the Iranian treatment system; during the 
study, an average higher proportion of men received 
streptokinase than women (55.70% men and 
41.70% women). However, the impact of lower 
rates of revascularization is controversial. In some 
studies, older age and higher baseline risk are 
presented as the causes of higher rates of mortality 
in women.32,33 In addition, some studies inferred 
that treatment in women had no effect on short-
term survival from AMI.27,34 Case fatality rate of 
AMI in 2008-2009 was 29.46% less than in 2000-
2001 (in men 27.17% and in women 32.29%), 
which coincides with the results of other hospital 
registered studies.35-37 HR of 28 days case fatality 
rate of AMI in 2008-2009 was 0.69 (95% CI = 0.56-
0.82) compared with 2000-2001; for men and 
women, it was 0.63 (95% CI = 0.45-0.88) and 0.70 
(95% CI = 0.54-0.90), respectively. A similar result 
was obtained in a European register on acute 
coronary syndrome, that compared 30 days 
mortality in 2000 and 2004 [odds ratio (OR) = 0.85  
(0.73-0.99)].38 In the study by MacIntyre et al., 28 
days case fatality rate increased with increasing of 
age.39 However, in this study, with the rising trend 
in mean age in the disease occurrence a steady 
decline was observed in case fatality rate. It is 
evident that the severity of infarctions decreased 
over time. A hypothesis is that the increasing use of 
medications such as aspirin and β-blockers before 
admission may reduce the size and severity of 
infarctions.40 Therefore, over time this could be 
effective in reducing the AMI case fatality rate. 
Population-based studies all documented a 
favorable decline in early mortality among younger 
individuals contrasting with a persistently high 
fatality rate among the elderly over a period of time 
ranging from 1975 to 1995.2,41-44 More importantly, 
the mortality rate of infarction in the community 
remained high and was consistently higher than that 
reported in clinical trials, reflecting their inherent 
selection processes.45 Although only clinical trials 
can test the efficacy of a new treatment, reports 
from community surveillance present important 
complementary insights into the effectiveness of 
care and treatments once implement. The current 
study demonstrates that the marked improvement 
in early fatalities after MI persisted over time and 
that notable survival gains were realized among the 
women and elderly, in whom discrepancy had been 
detected previously.43 This article was conducted 
based on the MONICA project in Isfahan with the 
support and ethical approval of ICRC with the code 
84130, in year 2012. 
Limitations 
A difficulty of this study is a lack of complete, 
community-based case ascertainment, which 
includes protocols for finding community fatal and 
non-fatal MI cases who are not admitted to 
hospitals. Most important limitation of the study is 
the lack of data about out-of-hospital fatal cases, 
such as MI cases managed at home or in health 
centers. This figure might be unimportant since MI 
event is considered an emergency in the Iranian 
health care system, and all hospitals should admit 
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such patients regardless of their insurance status. In 
the Danish MONICA population, this figure was 
measured to be > 01% of total MI cases in a year.46 
Therefore, omitting these patients will not lead to a 
sham decline in MI case fatality rates. 
Conclusion 
We have demonstrated a consistent decrease in case 
fatality rate following a first MI in Isfahan, during a 
10-year period from 2000 to 2009. The decrease in 
the trend of case fatality rate in both genders and all 
age groups was observable. There was 29.46% 
reduction in case fatality rate in the final period 
(2008-2009) compared to the primary period  
(2000-2001); 27.17% in men and 32.29% in women. 
A 60%, 60%, 19.31%, and 46.75% reduction was 
observed in the ≤ 40 years, 41-60 years, 61-80 years, 
and ≥ 80 years age groups, respectively. 
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